BTIG Research Begins Coverage on Matinas BioPharma (MTNB)

Research analysts at BTIG Research started coverage on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a report released on Friday, The Fly reports. The firm set a “buy” rating on the stock.

Other research analysts have also issued reports about the stock. Roth Capital began coverage on shares of Matinas BioPharma in a research report on Monday, February 11th. They set a “buy” rating and a $4.75 price target on the stock. Zacks Investment Research raised shares of Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Tuesday, April 16th. Finally, Maxim Group reissued a “buy” rating and set a $5.00 price target on shares of Matinas BioPharma in a research report on Thursday.

Matinas BioPharma stock opened at $0.94 on Friday. Matinas BioPharma has a 1-year low of $0.32 and a 1-year high of $1.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01).

A number of hedge funds have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in Matinas BioPharma in the first quarter worth about $7,432,000. Broadfin Capital LLC purchased a new position in shares of Matinas BioPharma in the first quarter worth about $2,973,000. IFP Advisors Inc increased its stake in shares of Matinas BioPharma by 222.0% in the fourth quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock worth $1,083,000 after purchasing an additional 1,223,828 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Matinas BioPharma in the first quarter worth about $1,867,000. Finally, J. Goldman & Co LP purchased a new position in shares of Matinas BioPharma in the first quarter worth about $1,139,000.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Featured Story: Technical Analysis

The Fly

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.